|
PYCARD expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.45910000041106E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.42529999971985E-07 |
| Normal-vs-Stage2 |
3.632200E-02 |
| Normal-vs-Stage3 |
1.96879999969646E-07 |
| Normal-vs-Stage4 |
2.42359999998998E-05 |
| Stage1-vs-Stage2 |
5.434400E-02 |
| Stage1-vs-Stage3 |
1.205770E-01 |
| Stage1-vs-Stage4 |
6.967200E-01 |
| Stage2-vs-Stage3 |
2.071600E-02 |
| Stage2-vs-Stage4 |
9.336400E-02 |
| Stage3-vs-Stage4 |
3.665600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.52479999737665E-08 |
| Normal-vs-AfricanAmerican |
4.461100E-03 |
| Normal-vs-Asian |
2.19129999999845E-05 |
| Caucasian-vs-AfricanAmerican |
1.492830E-01 |
| Caucasian-vs-Asian |
9.950600E-01 |
| AfricanAmerican-vs-Asian |
3.058400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.07920000000672E-07 |
| Normal-vs-Female |
2.99120000002429E-06 |
| Male-vs-Female |
1.806780E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.49700000010122E-07 |
| Normal-vs-Age(41-60Yrs) |
2.81040000005284E-06 |
| Normal-vs-Age(61-80Yrs) |
2.20399999999454E-05 |
| Normal-vs-Age(81-100Yrs) |
4.117100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.291400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.424600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.308000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.770200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.041200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.701800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.194200E-01 |
| Classical-VS-Follicular |
5.151500E-04 |
| Classical-VS-Other |
3.852600E-01 |
| Classical-VS-Normal |
1.1969000002221E-07 |
| Tall-VS-Follicular |
2.226400E-02 |
| Tall-VS-Other |
5.380800E-01 |
| Tall-VS-Normal |
9.98850000000218E-05 |
| Follicular-VS-Other |
5.461500E-02 |
| Follicular-VS-Normal |
3.908000E-02 |
| Other-VS-Normal |
1.555590E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.61089999953334E-07 |
| Normal-vs-N1 |
1.12480000002968E-06 |
| N0-vs-N1 |
3.875200E-01 |
|
|
